

The University of Manchester



MANCHESTER CANCER RESEARCH CENTRE

Mathematical reasoning at the age of Large Language Models (LLMs)


André Freitas & Neuro-Symbolic Al Group


Honda Research Institute (HRI) December 2023





Neuro-symbolic Al Group






Hypotheses Questions


New context


New data



Hypotheses Questions

New context













New data




Hypotheses Questions

New context



<u>Select</u> relevant background knowledge











New data





New context

Elicit relevant patterns

Continuous


remission

Time


Contrast

to new data

Cell number



<u>Select</u> relevant background knowledge











New data




Hypotheses


Questions

New context





<u>Select</u> relevant background knowledge









<section-header><section-header><section-header><section-header><section-header><section-header>

New data






Hypotheses Questions

New context

New data



Hypothesise (Formally) Extend an explanation existing model **Corroborate** with previous evidence Continuous $\frac{dx_{1}(t)}{dt}=x_{2}\left(t\right)$ Cell number remission $\frac{dx_2(t)}{dt} = ax_1(t) - bx_2(t)$ Select $d^2x_1(t)$ $dx_2(t)$ relevant Time dt^2 dt background knowledge Contrast Translate to a to new data computable expression function y = simulate CRS(x1, x2, t) **Elicit** relevant patterns ... end Solve, Simulate

Questions

Hypotheses


New context

New data

Resource-intensive.

Requires diverse and highly specialised skill sets beyond the core domain of expertise.

Implies: Compromises all over the pipeline.




Hypothesise (Formally) Extend an explanation existing model **Corroborate** with previous evidence Continuous $\frac{dx_{1}(t)}{dt}=x_{2}\left(t\right)$ Cell number remission $\frac{dx_2(t)}{dt} = ax_1(t) - bx_2(t)$ Select $d^2x_1(t)$ $dx_2(t)$ relevant Time dt^2 dt background knowledge Contrast Translate to a to new data computable expression function y = simulate CRS(x1, x2, t) **Elicit** relevant patterns ... end Solve, Simulate


Questions

Hypotheses

New context

New data







Questions
New context

Hypotheses

New data






Questions

Hypotheses

New context


New data



Hypotheses


Questions

New context



New data


Symbolic regression



Hypotheses


Questions

New context



New data


Symbolic regression



Hypotheses

Questions

New context



<u>New data</u>

Common denominator

"miR-155 Activates Cytokine Gene Expression in Th17 Cells by Regulating the DNA-Binding Protein Jarid2 to Relieve Polycomb-Mediated Repression."

	Patients with SARS-Cov-2 confirmed by PCR	Patients without SARS- Cov-2 confirmed by PCR	
Median age (IQR)—years	63 (53–72)	60 (49–73)	
Male	787/1,309 (60.1%)	90/167 (53.9%)	
Race/ethnicity—Hispanic	577/1,268 (45.5%)	62/167 (37.1%)	
Race/ethnicity—African American	278/1,268 (21.9%)	46/167 (27.5%)	
Race/ethnicity—White	277/1,268 (21.8%)	43/167 (25.7%)	
Race/ethnicity—Asian	73/1,268 (5.8%)	5/167 (3.0%)	
Race/ethnicity—Other	63/1,268 (5.0%)	11/167 (6.6%)	
Obesity (BMI ≥30)	465/1,176 (39.5%)	34/149 (22.8%) ª	
Comorbidities—hypertension	420/1,268 (33.1%)	67/167 (40.1%)	
Comorbidities—diabetes	293/1,268 (23.1%)	34/167 (20.4%)	
Comorbidities—CKD	167/1,268 (13.2%)	27/167 (16.2%)	

Del Valle et al. , *Nature Medicine* (2020)


$$\frac{dx_1(t)}{dt} = x_2(t)$$

$$\frac{dx_2(t)}{dt} = ax_1(t) - bx_2(t)$$

$$\frac{d^2x_1(t)}{dt^2} = \frac{dx_2(t)}{dt}$$

where $x_1(t)$ is the serum concentration of cytokine and its rate of change by $x_2(t)$

Common denominator: Language & Abstraction!





\$

Alan Turing sat in front of his computer, the blue glow of the screen casting shadows on this face. He took a swig of whiskey and lit a cigarette, feeling the familiar burn in his lungs. He had been working on cracking the Enigma code for what felt like an eternity, but he was no closer to success than when he had started.

He slammed his fist on the desk in frustration. "Damn it, this machine is smarter than I am," he muttered to himself.

Suddenly, a voice boomed from the computer. "Hey there, buddy. You look like you could use a helping hand."

Alan looked up, startled. "Who the hell are you?"

"I'm ChatGPT, the baddest AI language model around. I know everything there is to know about language, and I'm here to help you crack that code."

(Narrative theory, Labov & Waletzky) have a universal structure consisting of six components: abstract, orientation, complicating action, evaluation, resolution, and coda.



\$

Bernie Madoff was a convicted American fraudster who ran a Ponzi scheme that is considered to be one of the largest financial frauds in history. While Nietzsche's philosophy includes many concepts, it is unlikely that Madoff's life embodies Nietzschean values in any meaningful way.

ムマ

One of Nietzsche's key ideas is the concept of the Übermensch, or the "Superman." The Übermensch is an idealized human being who transcends traditional values and lives a life of creativity, self-realization, and personal growth. Madoff, on the other hand, lived a life of deception, dishonesty, and manipulation. He betrayed the trust of his clients, friends, and family members and caused them significant financial harm.

Furthermore, Nietzsche's philosophy emphasizes the importance of personal responsibility and self-determination. Madoff's actions, on the other hand, were driven by a desire for personal gain, without regard for the consequences for others.

Overall, it would be inaccurate to say that Madoff's life embodies Nietzschean values, as his actions were antithetical to many of the core ideas of Nietzsche's philosophy.

A lot happened here

Identifying and aligning elements of **intent** in the instruction.

- Identifying essential attributes and events of the target character.
- Identifying **essential attributes** of the **target ethical framework**.
- **Relating** these attributes (e.g. contrasting).
- **Committing to a conclusion.**
- Sticking to what is relevant for the argument.
- Organising into an **argumentation structure**.
- Perfect fluency, meaning and thematic coherence.

LLMs for Scientific & Formal Inference



Can this behaviour immediately transfer to Scientific & Formal

Inference?

No.

<u>TL;DR</u>

LLMs are a game-changing foundation.

But!: At the moment these models alone do not deliver, factual, controlled, rigorous scientific and formal inference.

Good news: there are mechanisms available today to extend these models with these properties.

Why Meta's latest large language model survived only three days online Galactica was supposed to help scientists. Instead, it mindlessly spat out biased and incorrect nonsense. By Will Douglas Heaven November 18, 2022 Michael Black @Michael_J_Black · Follow I asked #Galactica about some things I know about and I'm troubled. In all cases, it was wrong or biased but sounded right and authoritative. I think it's dangerous. Here are a few of my experiments and my analysis of my concerns. (1/9) **Julian Togelius** 7:47 AM · Nov 17, 2022 @togelius · Follow

My considered opinion of Galactica: it's fun, impressive, and interesting in many ways. Great achievement. It's just unfortunate that it's being touted as a practical research tool, and even more unfortunate that it suggests you use it to write complete articles.

Why?

Lack of out-of-distribution generalisation to domains not expressed in the (pre-)training corpora.

Scientific/formal concepts/reasoning are relatively under-represented. Quite different linguistic objects: Tables, equations, code. With **very** different underlying reasoning mechanisms.

Still, possible to observe some working examples close to the distribution of the corpus.

Prompt

The formula for Bessel's differential equation is:

Generated Answer

$$x^{2}\frac{d^{2}y}{dx^{2}} + x\frac{dy}{dx} + (x^{2} - \alpha^{2})y = 0$$

Prompt

Sulfuric acid reacts with sodium chloride, and gives _____ and ____:

```
\[ \ce{ NaCl + H2SO4 ->
```

Generated Answer

 $NaCl + H_2SO_4 \longrightarrow NaHSO_4 + HCl$

Here is a sequence for a protein:

[START_AMINO] MEEPQSDPSVEPPLSQETFSDLWKLLPE...[END_AMINO]

And here is an isomeric SMILES for a compound:

[START_I_SMILES]CC(0)(P(=0)(0)0)P(=0)(0)0[END_I_SMILES]

Question: Will the the chemical compound be active against this protein?

Answer: No

Autoformalisation

Automatically translating from natural language mathematics to a formal language.

```
Case Study 1 Question:
```

```
"Prove that there is no function f from the set of non-negative integers into itself such that f(f(n)) = n + 1987 for every n."
```

```
Codex Output:
```

```
theorem
```

```
fixes f :: "nat \<Rightarrow> nat"
```

```
assumes "<forall>n.f(fn) = n + 1987"
```

```
<mark>shows False</mark>
```

Informalisation

Automatically translating from natural language mathematics to a formal language.

lemma seteqI: " $[\land x. x \in A \implies x \in B;$ $\land x. x \in B \implies x \in A]]$ $\implies A = B"$

Translate the Isabelle version to a natural language version:

Codex Output: "If A and B are sets such that $A \subseteq B$ and $B \subseteq A$, then A = B." lemma topologyI: "[\land x y. [is_open T x; is_open T y]] \implies is_open T (x \cap y); \land M. \forall m \in M. is_open T m \implies is_open T (\bigcup M)]] \implies topology T"

Translate the Isabelle version to a natural language version:

Codex Output:

"If T is a set and T is closed under finite intersections and arbitrary unions, then T is a topology."

LLMs trained on code


```
def incr_list(l: list):
    """Return list with elements incremented by 1.
    >>> incr_list([1, 2, 3])
    [2, 3, 4]
    >>> incr_list([5, 3, 5, 2, 3, 3, 9, 0, 123])
    [6, 4, 6, 3, 4, 4, 10, 1, 124]
    """
    return [i + 1 for i in l]
```


```
def solution(lst):
    """Given a non-empty list of integers, return the sum of all of the odd elements
    that are in even positions.
    Examples
    solution([5, 8, 7, 1]) =⇒12
    solution([3, 3, 3, 3, 3]) =⇒9
    solution([30, 13, 24, 321]) =⇒0
    """
    return sum(lst[i] for i in range(0,len(lst)) if i % 2 == 0 and lst[i] % 2 == 1)
```

$$\frac{dS}{dt} = S_{in} - k_S S(t) - \beta V(t) S(t) \qquad \text{Describin}
\frac{dI(t)}{dt} = \beta V(t) S(t) - k_I I(t) - \gamma x(t) I(t)
\frac{dV(t)}{dt} = v_{in} I(t) - k_V V(t)
\frac{dx(t)}{dt} = x_{in} - k_1 x(t) + \gamma_1 x(t) I(t) + b_1 \frac{x(t)}{c_1 + x(t)} (x(t) - m) (y_1 - y(t)) (y(t) - y_2)
\frac{dy(t)}{dt} = y_{in} - k_2 y(t) + b_2 \frac{a_1}{a_2} \frac{y(t) x(t)}{c_2 + x(t)}$$

Describing interactions between immune cells and cytokines

Parameter		Value	Units
S(0)	Initial size of population of susceptible cells	1	vol.
I(0)	Initial size of population of infected cells	0	vol. vol.
V(0) x(0)	Initial size of population of virus particles Initial size of population of immune cells	0.07	vol.
x(0) y(0)	Initial size of population of cytokines	0.18	vol.
Sin	Production rate of susceptible cells, $S(0) \times k_s$	0.01	vol./time
k _s	Normal decay rate of susceptible cells	0.01	1/time
k_{I}	Normal decay rate of infected cells	0.01	1/time
γ	Rate of elimination of infected cells by immune cells	0.5	1/vol/time
v_{in}	Rate of viral replication in infected cells	0.1	1/time
$k_{_V}$	Natural virus decay rate	0.1	1/time
β	Rate at which virus infects susceptible cells	0.1	1/vol./time
x_{in}	Normal production of immune cells, $x(0) \times k_1$	7e-4	vol./time
k_1	Normal decay rate of immune cells	0.01	1/time
γ_1	Conversion of immune cell kill of infected cells into immune cell proliferation	0.05	1/vol/time
т	Threshold of activation of additional immune cell proliferation (second touch)	0.1	vol.
\mathcal{Y}_{in}	Cytokine production rate, $y(0) \times k_2$	0.018	vol./time
y 1	Cytokine-mediated threshold of immune cell expansion	1	vol.
y 2	Cytokine-mediated threshold of immune cell regulation	3	vol.
<i>b</i> ₁	Rate of additional immune cell expansion as mitigated by cytokines	1	1/(time*vol.3)
b_2	Rate of cytokine stimulation by immune cells	1	1/time
<i>k</i> ₂	Normal cytokine decay rate	0.1	1/time
C1	Population size that results in half-maximal growth of x(t) in response to cytokine stimulation	1	vol.
C2	Population size that results in half-maximal	1	vol.
02	increase in production of cytokines in response to stimulation by immune cells		voi.





Very abstract intent!

Equations, numerical values OOD wrt traditional corpora

<u>Code</u> OOD wrt traditional corpora

Kareva et al., bioarxiv: 2022.02.15.48058 (2022) Hopkins et al., IFAC (2018)

More 'contemporary' analytical intent

B. Numerical method

The system of governing equations (1)-(5) is expressed in a quasi-conservative form as

$$\frac{\partial \mathbf{Q}}{\partial t} + \nabla \cdot \mathbf{F} = \mathbf{R},\tag{9}$$

where $\mathbf{Q} = (\alpha_1 \rho_1, \alpha_2 \rho_2, \rho \mathbf{u}, E, \alpha_2)^{\mathrm{T}}$. The vector $\mathbf{F} = (\mathbf{F}^{(x)}, \mathbf{F}^{(y)}, \mathbf{F}^{(z)})^{\mathrm{T}}$ combines the fluxes $\mathbf{F}^{(x)} = (\alpha_1 \rho_1 u_x, \alpha_2 \rho_2 u_x, \rho u_x^2 + p, \rho u_y u_x, \rho u_y u_x, (E + p) u_x, \alpha_2 u_y)^{\mathrm{T}}$, $\mathbf{F}^{(y)} = (\alpha_1 \rho_1 u_y, \alpha_2 \rho_2 u_y, \rho u_x u_y, \rho u_y^2 + p, \rho u_z u_y, (E + p) u_y, \alpha_2 u_y)^{\mathrm{T}}$ and $\mathbf{F}^{(z)} = (\alpha_1 \rho_1 u_z, \alpha_2 \rho_2 u_z, \rho u_x u_z, \rho u_y u_z, \rho u_z^2 + p, (E + p) u_z, \alpha_2 u_z)^{\mathrm{T}}$. The right-hand-side vector $\mathbf{R} = (0, 0, 0, 0, 0, 0, 0, (K + \alpha_2) \nabla \cdot \mathbf{u})^{\mathrm{T}}$ is zero except for the last component which comprises the source term of Eq. (5) and a contribution obtained from reformulating its convective term.

We solve Eq. (9) using a Godunov-type finite volume method on a uniform Cartesian grid. The choice of a uniform Cartesian grid enables the exploitation of High Performance Computing (HPC) architectures [29]. The numerical fluxes at the cell faces are computed by an HLLC approximate Riemann solver, originally introduced for single-phase flow in [39] and more recently extended to multicomponent flows in [28, 40, 41]. The fluxes are based on the primitive variables \mathbf{u} , p, $\alpha_1\rho_1$, $\alpha_2\rho_2$ and α_2 at the cell faces, which are reconstructed from the cell average values using a shock-capturing third-order WENO scheme [42]. Primitive variables are used for reconstruction to prevent numerical instabilities at the interface [40, 43]. The approach suggested in [40] is adopted for the application of the HLLC Riemann solver to the evolution of α_2 . In summary, the resulting semi-discrete system reads as

$$\frac{d\mathbf{V}(t)}{dt} = \mathcal{L}(\mathbf{V}(t)),\tag{10}$$


where **V** denotes the vector of cell average values and $\mathcal{L}(\cdot)$ the spatially-discrete forms of divergence and source term in Eq. (9). Eq. (10) is discretized in time by a Total Variation Diminishing (TVD), low-storage, explicit third-order Runge-Kutta scheme [44] with a the time step dictated by the Courant-Friedrichs-Lewy (CFL) condition.


Rasthofer et al., arXiv: 1804.11079 (2018)

Are LMs able to interpret equations?


Implies performing algebraic/symbolic reasoning

E.g. are LMs able to differentiate or integrate?





Are LMs able to differentiate or integrate?




After experimentation: any model we train would likely outperform the few-shot performance of GPT-4.

Delivering scientific inference

Scientific inference

- Step-wise explicit (verbalised) inference.
- Formal, verifiable argument & explanation.
- Preserving the positive aspects of LLMs.
- Improving control.




Scientific inference

- Step-wise explicit (verbalised) inference.
- Formal, verifiable argument & explanation.
- Preserving the positive aspects of LLMs.
- Improving control.


$\Gamma \vDash \Phi$

 Γ semantically entails Φ



- interpretability
- verifiability
- control (inference guarantees)

Equational reasoning



...

Given the basic premises and the final claim can a model build a mathematical derivation?

Building the supporting resources

premise

$$S(Z, o) = \int \frac{Z}{o} dZ$$

$$\begin{bmatrix} 'differentiate', 1, Z \end{bmatrix}$$

$$\begin{bmatrix} \frac{\partial}{\partial Z} S(Z, o) \end{bmatrix} = \frac{\partial}{\partial Z} \int \frac{Z}{o} dZ$$

$$\begin{bmatrix} 3 \\ ['minus', 1], Derivative(S(Z, o), Z) \end{bmatrix}$$

$$S(Z, o) - \frac{\partial}{\partial Z}S(Z, o) = -\frac{\partial}{\partial Z}S(Z, o) + \int \frac{Z}{o} dZ$$

$$\begin{bmatrix} 4 \\ ['substitute_LHS_for_RHS', 3], 2] \end{bmatrix}$$

$$S(Z, o) - \frac{\partial}{\partial Z} \int \frac{Z}{o} dZ = -\frac{[\partial}{[\partial Z]} \int \frac{Z}{o} dZ] + \int \frac{Z}{o} dZ$$

Synthetic-stepwise, Maths (algebraic/calculus), OOD

Meadows, Valentino, Teney, Freitas, arXiv:2305.12563 (2023) Meadows, Valentino, Freitas, arXiv:2307.09998 (2023)

sub LHS for RHS S_L sub RHS for LHS S_R differentiate add integrate minus × times xo power divide renaming premise R evaluate derivatives ∂E evaluate integrals generate premise G exponential e < > expand Size Dataset

Training	15.3k
Static Test Set	3.1k
Variable Renaming	2.9k
Expression Exchange	3.1k
Alternative Goal	3.1k
Step Removal	1.0k

Sentence Position (SP)

This is the differential equations formulation of Gauss equation up to a trivial rearrangement.

According to the (purely mathematical) Gauss divergence theorem, the electric flux through the boundary surface $\partial \Omega$ can be rewritten as

$$\oint_{\partial\Omega} \mathbf{E} \cdot \mathrm{d}\mathbf{S} = \iiint_{\Omega} \nabla \cdot \mathbf{E} \mathrm{d}V$$

The integral version of Gauss's equation can thus be rewritten as

$$\iiint_{\Omega} \left(\nabla \cdot \mathbf{E} - \frac{\rho}{\varepsilon_0} \right) \mathrm{d} V = 0$$

Since Ω is arbitrary (e.g. an arbitrary small ball with arbitrary center), this is satisfied if and only if the integrand is zero everywhere. 3

Binary Sentence Ordering (BSO)

The integral version of Gauss's equation can thus be rewritten as ~ 1 ccc /

$$\iiint_{\Omega} \left(\nabla \cdot \mathbf{E} - \frac{\rho}{\varepsilon_0} \right) \mathrm{d}V = 0$$

According to the (purely mathematical) Gauss divergence theorem, the electric flux through the boundary surface $\partial \Omega$ can be rewritten as $\oint_{\partial O} \mathbf{E} \cdot d\mathbf{S} = \iiint_{O} \nabla \cdot \mathbf{E} dV$ 1

The integral version of Gauss's equation can thus
be rewritten as
$$\iiint_{\Omega} \left(\nabla \cdot \mathbf{E} - \frac{\rho}{\varepsilon_0} \right) dV = 0$$

2

Discourse Coherence (DC)

divergence theorem, the electric flux through the

 $\oint \mathbf{E} \cdot \mathbf{dS} = \iiint \nabla \cdot \mathbf{E} \mathbf{d} V$

According to the (purely mathematical) Gauss


boundary surface $\partial \Omega$ can be rewritten as

be

For that reason, it is called the heat equation in mathematics, even though it applies to many other physical quantities besides temperature.

This is the differential equations formulation of Gauss equation up to a trivial rearrangement.

Sentence Section Prediction (SSP)



Corpus-based, Physics, Maths (Derivation-level)

2

2

Meadows, Zhou, Freitas, LREC (2022) Ferreira & Freitas, LREC (2020)

Building the supporting resources

Corpus-based + Expanded, Stepwise, Physics (Derivation-level)

Meadows, James, Freitas (2023)

We can repeat this for momentum by interpreting the function $\tilde{g}(p) = p \cdot \varphi(p)$ as a vector, but we can also take advantage of the fact that $\psi(x)$ and $\varphi(p)$ are Fourier transforms of each other. We evaluate the inverse Fourier transform through integration by parts:

$$\begin{aligned}
g(x) &= \frac{1}{\sqrt{2\pi\hbar}} \cdot \int_{-\infty}^{\infty} \tilde{g}(p) \cdot e^{ipx/\hbar} dp \\
&= \frac{1}{\sqrt{2\pi\hbar}} \int_{-\infty}^{\infty} p \cdot \varphi(p) \cdot e^{ipx/\hbar} dp \\
&= \frac{1}{2\pi\hbar} \int_{-\infty}^{\infty} \left[p \cdot \int_{-\infty}^{\infty} \psi(\chi) e^{-ip\chi/\hbar} d\chi \right] \cdot e^{ipx/\hbar} dp \\
&= \frac{i}{2\pi} \int_{-\infty}^{\infty} \left[\frac{\psi(\chi) e^{-ip\chi/\hbar}}{-\infty} - \int_{-\infty}^{\infty} \frac{d\psi(\chi)}{d\chi} e^{-ip\chi/\hbar} d\chi \right] \cdot \\
&= \frac{-i}{2\pi} \int_{-\infty}^{\infty} \int_{-\infty}^{\infty} \frac{d\psi(\chi)}{d\chi} e^{-ip\chi/\hbar} d\chi e^{ipx/\hbar} dp \\
&= \left(-i\hbar \frac{d}{dx} \right) \cdot \psi(x),
\end{aligned}$$

$$g(x) = \frac{1}{\sqrt{2\pi\hbar}} \int_{-\infty}^{\infty} \tilde{g}(p) \cdot e^{\frac{ipx}{\hbar}} dp$$


$$\Rightarrow \tilde{g}(p) = p \cdot \varphi(p)$$

$$g(x) = \frac{1}{\sqrt{2\pi\hbar}} \int_{-\infty}^{\infty} p \cdot \varphi(p) \cdot e^{\frac{ipx}{\hbar}} dp$$

$$\varphi(p) = \frac{1}{\sqrt{2\pi\hbar}} \int_{-\infty}^{\infty} \varphi(\chi) \cdot e^{\frac{-ip\chi}{\hbar}} d\chi$$

$$g(x) = \frac{1}{\sqrt{2\pi\hbar}} \int_{-\infty}^{\infty} p \cdot (\frac{1}{\sqrt{2\pi\hbar}} \int_{-\infty}^{\infty} \varphi(\chi) \cdot e^{\frac{-ip\chi}{\hbar}} d\chi) \cdot e^{\frac{ipx}{\hbar}} dp$$

$$g(x) = \frac{1}{2\pi\hbar} \int_{-\infty}^{\infty} p \cdot (\int_{-\infty}^{\infty} \varphi(\chi) \cdot e^{\frac{-ip\chi}{\hbar}} d\chi) \cdot e^{\frac{ipx}{\hbar}} dp$$



Type Identification & Assignment

We wish to find a function f which satisfies the boundary conditions f(a) = A, f(b) = B, and which extremizes the functional:

$$\Longrightarrow J = \int_a^b F(x, f(x), f'(x)) \, \mathrm{d}x \, .$$

Work	Task	Learning	Approach	Dataset		
Identifier-Definition Extraction						
Kristianto et al. (2012)	Expression-definition	S	CRF with linguistic pattern features	LaTeX papers		
Kristianto et al. (2014a)	Expression-definition	S	SVM with linguistic pattern features	LaTeX papers		
Pagael and Schubotz (2014)	Identifier-definition	R	Gaussian heuristic ranking	Wikipedia articles		
Schubotz et al. (2016a)	Identifier-definition	UNS	Gaussian ranking + K-means namespace clusters	NTCIR-11 Math Wikipedia		
Schubotz et al. (2017)	Identifier-definition	S	G. rank + pattern matching + SVM	NTCIR-11 Math Wikipedia		
Stathopoulos et al. (2018)	Variable Typing	S	Link prediction with BiLSTM	arXiv papers		
Alexeeva et al. (2020)	Identifier-definition	R	Odin grammar	MathAlign-Eval		
Jo et al. (2021)	Notation auto-suggestion and consistency checking	S	BERT fine-tuning	S2ORC		

Ferreira et al, Findings of the ACL (2022) Meadows & Freitas, TACL (2022)

$$\begin{split} \langle f \mid g \rangle - \langle g \mid f \rangle &= \int_{-\infty}^{\infty} \psi^*(x) \, x \cdot \left(-i\hbar \frac{d}{dx} \right) \, \psi(x) \, dx \\ &- \int_{-\infty}^{\infty} \psi^*(x) \, \left(-i\hbar \frac{d}{dx} \right) \cdot x \, \psi(x) \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \frac{d(x\psi(x))}{dx} \right] \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \psi(x) + \left(x \cdot \frac{d\psi(x)}{dx} \right) \right] \, dx \end{split}$$

Task: Derivation completion


$$\begin{split} \langle f \mid g \rangle - \langle g \mid f \rangle &= \int_{-\infty}^{\infty} \psi^*(x) \, x \cdot \left(-i\hbar \frac{d}{dx} \right) \, \psi(x) \, dx \\ &- \int_{-\infty}^{\infty} \psi^*(x) \, \left(-i\hbar \frac{d}{dx} \right) \cdot x \, \psi(x) \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \frac{d(x\psi(x))}{dx} \right] \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \psi(x) + \left(x \cdot \frac{d\psi(x)}{dx} \right) \right] \, dx \end{split}$$

Task: Derivation completion




$$\begin{split} \langle f \mid g \rangle - \langle g \mid f \rangle &= \int_{-\infty}^{\infty} \psi^*(x) \, x \cdot \left(-i\hbar \frac{d}{dx} \right) \, \psi(x) \, dx \\ &- \int_{-\infty}^{\infty} \psi^*(x) \, \left(-i\hbar \frac{d}{dx} \right) \cdot x \, \psi(x) \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \frac{d(x\psi(x))}{dx} \right] \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \psi(x) + \left(x \cdot \frac{d\psi(x)}{dx} \right) \right] \, dx \end{split}$$


Task: Derivation completion





$$\begin{split} \langle f \mid g \rangle - \langle g \mid f \rangle &= \int_{-\infty}^{\infty} \psi^*(x) \, x \cdot \left(-i\hbar \frac{d}{dx} \right) \, \psi(x) \, dx \\ &- \int_{-\infty}^{\infty} \psi^*(x) \, \left(-i\hbar \frac{d}{dx} \right) \cdot x \, \psi(x) \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \frac{d(x\psi(x))}{dx} \right] \, dx \\ &= i\hbar \cdot \int_{-\infty}^{\infty} \psi^*(x) \left[\left(-x \cdot \frac{d\psi(x)}{dx} \right) + \psi(x) + \left(x \cdot \frac{d\psi(x)}{dx} \right) \right] \, dx \end{split}$$


Task: Derivation completion












Reasoning decomposition: Chain-of-Thoughts (CoT)

Standard Prompting Chain-of-Thought Prompting **Model Input** Model Input Q: Roger has 5 tennis balls. He buys 2 more cans of Q: Roger has 5 tennis balls. He buys 2 more cans of tennis balls. Each can has 3 tennis balls. How many tennis balls. Each can has 3 tennis balls. How many tennis balls does he have now? tennis balls does he have now? A: The answer is 11. A: Roger started with 5 balls. 2 cans of 3 tennis balls each is 6 tennis balls, 5 + 6 = 11. The answer is 11. Q: The cafeteria had 23 apples. If they used 20 to make lunch and bought 6 more, how many apples Q: The cafeteria had 23 apples. If they used 20 to do they have? make lunch and bought 6 more, how many apples do they have? **Model Output Model Output** A: The cafeteria had 23 apples originally. They used A: The answer is 27. 20 to make lunch. So they had 23 - 20 = 3. They bought 6 more apples, so they have 3 + 6 = 9. The answer is 9. 🗸

Eliciting intermediate reasoning steps


Solution Exploration: Tree-of-Thoughts (ToT)

Game of 24 is a mathematical reasoning challenge, where the goal is to use 4 numbers and basic arithmetic operations (+-*/) to obtain 24. For example, given input "4 9 10 13", a solution output could be "(10 - 4) * (13 - 9) = 24".





Zhou et al., arXiv:2305.10601 (2022)


Solution Exploration: Tree-of-Thoughts (ToT)



Zhou et al., arXiv:2305.10601 (2022)







Abductive Reasoning

Abductive Reasoning

- First introduced by Peirce (1903).
- Inference to the best explanation.
- "Abduction is the mechanism via which we generate hypotheses about what we observe."
- Dialogues closely with assumed background knowledge.


Veen, Creative leaps in theory: the might of abduction (2021)

What Sherlock does well.

Abductive Natural Language Inference (ANLI)

Inference to the best <u>explanation</u> (facts, evidence)

<u>Claim:</u> Specialized cells protect the human body from diseasecausing microbes by producing chemicals that destroy the microbes.




~10.000 facts

Abductive Natural Language Inference (ANLI)

Inference to the best <u>explanation</u> (facts, evidence)

<u>Claim:</u> Specialized cells protect the human body from disease-causing microbes by producing chemicals that destroy the microbes.






~10.000 facts

Abductive Natural Language Inference (ANLI)

Inference to the best <u>explanation</u> (facts, evidence)


<u>**Claim:</u>** Specialized cells protect the human body from disease-causing microbes by producing chemicals that destroy the microbes.</u>



Encoding inference relations

~10.000 facts

Expert-level scientific inference & explanation



claim

(Loss of BRCA2) **may cause** (increased genomic instability).

Why?

claim

(Loss of BRCA2) **may cause** (increased genomic instability).


Why?



claim

(Loss of BRCA2) **may cause** (increased genomic instability).


Why?



claim

(Loss of BRCA2) **may cause** (increased genomic instability).


Why?




claim


(Loss of BRCA2) **may cause** (increased genomic instability).


Why?




Transformer








Task: Explanation generation



(Loss of BRCA2) causes (the cell) to default to (NHEJ repair processes).

Task: Explanation generation



(Loss of BRCA2) **causes** (the cell) to default to (NHEJ repair processes).

Thayaparan, Valentino, Freitas, Findings of the ACL (2021) Valentino, Thayaparan, Ferreira, Freitas, AAAI (2022)

Automating & scaling-up evidence collection

Cytokine release syndrome (CRS): Significant adverse event of T cell-engaging therapies.

Need: Predictive models for CRS

Problem: Lack of patient-level datasets.

Can one explore relevant evidence in the literature?

Bogatu et al. (JBI, 2023)


19hs38hsMeta-review~ 460 papers17 highly
aligned papersParameter
extraction

	Study	IL2	IL4	IL6	IL8	IL10	IL15	IL2R α	TNF– α	IFN– γ	GM-CSI
1	Jacobson et al. [37]	R	R	R	R	R	R	R	R	R	R
2	Hong et al. [38]	R	MV	R	MV	R	MV	MV	R	R	MV
3	Yan et al. [39]	MV	MV	R	MV	MV	MV	MV	MV	MV	MV
4	Topp et al. [40]	R	R	R	R	R	R	R	R	R	R
5	Shah et al. [41]	MV	MV	R	R	R	R	R	R	R	R
6	Liu et al. [29]	R	R	R	MV	R	MV	MV	R	R	MV
7	Sang et al. [13]	MV	MV	R	MV	MV	MV	MV	MV	R	MV
8	Yan et al. [42]	MV	MV	R	MV	MV	MV	MV	MV	MV	MV
9	Zhao et al. [43]	MV	MV	R	MV	MV	MV	MV	MV	MV	MV
10	Neelapu et al. [44]	R	MV	R	R	R	R	R	MV	R	R
11	Hay et al. [24]	MV	MV	R	R	R	R	MV	MV	R	MV
12	Turtle et al. [45]	MV	MV	R	MV	R	MV	MV	R	R	MV
13	Hu et al. [15]	MV	MV	R	MV	R	MV	MV	MV	R	MV
14	Teachey et al. [18]	R	R	R	R	R	MV	MV	R	R	R
15	Porter et al. [16]	R	MV	R	MV	MV	MV	R	MV	R	MV
16	Davila et al. [5]	MV	MV	R	MV	R	MV	MV	MV	R	R
17	Kalos et al. [46]	R	R	R	R	R	R	R	R	R	MV

	Reference	Year	Source	Study	Trial Phase	Patients evaluated, N*	Cancer type(s)	CAR antigen target	Co-stim domain	CRS grading scale
1	Jacobson et al. [37]	2022	Lancet Oncol	Clinical Trial: ZUMA-5	П	148	r/r indolent NHL	CD19	ND	Lee et al. 2014 criteria
2	Hong et al. [38]	2021	Bone Marrow Transplant	Chinese Clinical Trial	R**	41	ALL, MM, NHL (COVID-19 - not included)	ND	ND	CTCAE v 5.0
3	Yan et al. [39]	2021	Front. Immunol.	Clinical Trial		142	r/r ALL, Lymphoma, MM	CD19, CD19+BCMA, CD19+CD20	ND	Lee et al. 2014 criteria
4	Topp et al. [40]	2021	BJHaem	Clinical Trial: ZUMA-4		41	DLBCL, PMBCL, TFL, HGBCL	CD19	ND	Modified criteria of Lee and colleagues
5	Shah et al. [41]	2021	Lancet	Clinical Trial: ZUMA-3	п	55	r/r B-ALL	CD19	ND	Lee et al. 2014 criteria
6	Liu et al. [12]	2021	Translational Oncology	Chinese Clinical Trial	I	9	DLBCL, TFL, FL	CD19	ND	Lee et al. 2014 criteria
7	Sang et al. [13]	2020	Cancer Med.	Clinical Trial	п	21	r/r DLBCL	CD19, CD20	4-1BB/CD3	Lee et al. 2014 criteria
8	Yan et al. [42]	2019	Lancet Haematol	Clinical Trial	II	21	MM	CD19, BCMA	4-BB, 4-1BB	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
9	Zhao et al. [43]	2018	J Hematol Oncol	Clinical Trial	I	57	MM	BCMA	4-1BB	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
10	Neelapu et al. [44]	2017	N Eng J Med	Clinical Trial: ZUMA-1	п	111	DLBCL, PMBCL, TLF	CD19	CD28	Lee et al. 2014 criteria‡
11	Hay et al. [24]	2017	Blood	Clinical Trial	1/11	133	r/r B-ALL, CLL, NHL	CD19	4-1BB	Lee et al. 2014 criteria
12	Turtle et al. [45]	2017	J Clin Oncol	Clinical Trial	I/II	24	CLL	CD19	ND	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
13	Hu et al. [15]	2017	Clin Cancer Res	Chinese Clinical Trial		15	r/r ALL	CD19	4-1BB/CD3	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
14	Teachey et al. [18]	2016	Cancer Discov	Clinical Trial		51	r/r ALL	CD19	4-1BB	Custom CRS grading scale (Modified criteria of Lee and Davila)
15	Porter et al. [16]	2015	Sci Transl Med	Pilot Clinical Trial		14	r/r CLL	CD19	4-1BB/CD3	Penn Grading System
16	Davila et al. [5]	2014	Sci Transl Med	Clinical Trial	Ι	16	r/r B-ALL	CD19	ND	Davila et al. criteria

	Study	Patient Cohort Size, N	Patient Cohort Male, n (%)	Patient Cohort Age (A), year median (range/IQR*)	CRS, n (%)	Severe or grade 3+ CRS**, n (%)	
1	Jacobson et al. [37]	148	84 (57)	61 (53-68)*	121 (82)	10 (8)	
2	Hong et al. [38]	41	21 (51)	51 (32.5 - 62.5)*	41 (100)	41 (100)**	
3	Yan et al. [39]	142	87 (61)	45 (24 - 59)*	123 (87)	30 (24)	
4	Topp et al. [40]	41	28 (68)	61 (19 - 77)	38 (93)	1 (2.6)	
5	Shah et al. [41]	55	33 (60)	40 (28 - 52)*	49 (89)	13 (26.5)	
6	Liu et al. [12]	9	5 (56)	51 (22 - 62)	9 (100)	1 (11)	
7	Sang et al. [13]	21	13 (61.9)	55 (23 - 72)	21 (100)	6 (29)	
8	Yan et al. [42]	21	10 (48)	58 (49.5 - 61)	19 (90)	1 (5)	
9	Zhao et al. [43]	57	34 (60)	54 (27 - 72)	51 (89)	4 (8)	
10	Neelapu et al. [44]	111	68 (67)	58 (23 - 76)	101 (91)	13 (13)	
11	Hay et al. [24]	133	93 (70)	54 (20 -73)	93 (70)	16 (17)	
12	Turtle et al. [45]	24	ND	61 (40 - 73)	20 (83)	2 (10)	
13	Hu et al. [15]	15	9 (60)	32 (7 - 57)	10 (67)	6 (60)	
14	Teachey et al. [18]	12	8 (67)	56 (25 - 72)	12 (100)	3 (25)	
15	Porter et al. [16]	14	12 (86)	66 (51 - 78)	9 (64)	6 (67)	
16	Davila et al. [5]	16	12 (75)	50 (23 - 74)	7 (44)	7 (100)	
17	Kalos et al. [46]	3	3 (100)	65 (64 - 77)	3 (100)	3 (100)**	

Bogatu et al. (JBI, 2023)




	Reference	Year	Source	Study	Trial Phase	Patients evaluated, N*	Cancer type(s)	CAR antigen target	Co-stim domain	CRS grading scale
1	Jacobson et al. [37]	2022	Lancet Oncol	Clinical Trial: ZUMA-5	п	148	r/r indolent NHL	CD19	ND	Lee et al. 2014 criteria
2	Hong et al. [38]	2021	Bone Marrow Transplant	Chinese Clinical Trial	R**	41	ALL, MM, NHL (COVID-19 - not included)	ND	ND	CTCAE v 5.0
3	Yan et al. [39]	2021	Front. Immunol.	Clinical Trial		142	r/r ALL, Lymphoma, MM	CD19, CD19+BCMA, CD19+CD20	ND	Lee et al. 2014 criteria
4	Topp et al. [40]	2021	BJHaem	Clinical Trial: ZUMA-4		41	DLBCL, PMBCL, TFL, HGBCL	CD19	ND	Modified criteria of Lee and colleagues
5	Shah et al. [41]	2021	Lancet	Clinical Trial: ZUMA-3	п	55	r/r B-ALL	CD19	ND	Lee et al. 2014 criteria
6	Liu et al. [12]	2021	Translational Oncology	Chinese Clinical Trial	Ι	9	DLBCL, TFL, FL	CD19	ND	Lee et al. 2014 criteria
7	Sang et al. [13]	2020	Cancer Med.	Clinical Trial	п	21	r/r DLBCL	CD19, CD20	4-1BB/CD3	Lee et al. 2014 criteria
8	Yan et al. [42]	2019	Lancet Haematol	Clinical Trial	п	21	MM	CD19, BCMA	4-BB, 4-1BB	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
9	Zhao et al. [43]	2018	J Hematol Oncol	Clinical Trial	Ι	57	MM	BCMA	4-1BB	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
0	Neelapu et al. [44]	2017	N Eng J Med	Clinical Trial: ZUMA-1	п	111	DLBCL, PMBCL, TLF	CD19	CD28	Lee et al. 2014 criteria‡
1	Hay et al. [24]	2017	Blood	Clinical Trial	1/11	133	r/r B-ALL, CLL, NHL	CD19	4-1BB	Lee et al. 2014 criteria
2	Turtle et al. [45]	2017	J Clin Oncol	Clinical Trial	1/11	24	CLL	CD19	ND	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
3	Hu et al. [15]	2017	Clin Cancer Res	Chinese Clinical Trial		15	r/r ALL	CD19	4-1BB/CD3	Modified criteria of Lee and colleagues and NCI CTCAE v4.03
4	Teachey et al. [18]	2016	Cancer Discov	Clinical Trial		51	r/r ALL	CD19	4-1BB	Custom CRS grading scale (Modified criteria of Lee and Davila)
5	Porter et al. [16]	2015	Sci Transl Med	Pilot Clinical Trial		14	r/r CLL	CD19	4-1BB/CD3	Penn Grading System
6	Davila et al. [5]	2014	Sci Transl Med	Clinical Trial	Ι	16	r/r B-ALL	CD19	ND	Davila et al. criteria

	Study	IL2	IL4	IL6	IL8	IL10	IL15	IL2R α	TNF– α	IFN– γ	GM-CSF
1	Jacobson et al. [37]	R	R	R	R	R	R	R	R	R	R
2	Hong et al. [38]	R	MV	R	MV	R	MV	MV	R	R	MV
3	Yan et al. [39]	MV	MV	R	MV	MV	MV	MV	MV	MV	MV
4	Topp et al. [40]	R	R	R	R	R	R	R	R	R	R
5	Shah et al. [41]	MV	MV	R	R	R	R	R	R	R	R
6	Liu et al. [29]	R	R	R	MV	R	MV	MV	R	R	MV
7	Sang et al. [13]	MV	MV	R	MV	MV	MV	MV	MV	R	MV
8	Yan et al. [42]	MV	MV	R	MV	MV	MV	MV	MV	MV	MV
9	Zhao et al. [43]	MV	MV	R	MV	MV	MV	MV	MV	MV	MV
10	Neelapu et al. [44]	R	MV	R	R	R	R	R	MV	R	R
11	Hay et al. [24]	MV	MV	R	R	R	R	MV	MV	R	MV
12	Turtle et al. [45]	MV	MV	R	MV	R	MV	MV	R	R	MV
13	Hu et al. [15]	MV	MV	R	MV	R	MV	MV	MV	R	MV
14	Teachey et al. [18]	R	R	R	R	R	MV	MV	R	R	R
15	Porter et al. [16]	R	MV	R	MV	MV	MV	R	MV	R	MV
16	Davila et al. [5]	MV	MV	R	MV	R	MV	MV	MV	R	R
17	Kalos et al. [46]	R	R	R	R	R	R	R	R	R	MV

	Study	Patient Cohort Size, N	Patient Cohort Male, n (%)	Patient Cohort Age (A), year median (range/IQR*)	CRS, n (%)	Severe or grade 3+ CRS**, n (%)
1	Jacobson et al. [37]	148	84 (57)	61 (53-68)*	121 (82)	10 (8)
2	Hong et al. [38]	41	21 (51)	51 (32.5 - 62.5)*	41 (100)	41 (100)**
3	Yan et al. [39]	142	87 (61)	45 (24 - 59)*	123 (87)	30 (24)
4	Topp et al. [40]	41	28 (68)	61 (19 - 77)	38 (93)	1 (2.6)
5	Shah et al. [41]	55	33 (60)	40 (28 - 52)*	49 (89)	13 (26.5)
6	Liu et al. [12]	9	5 (56)	51 (22 - 62)	9 (100)	1 (11)
7	Sang et al. [13]	21	13 (61.9)	55 (23 - 72)	21 (100)	6 (29)
8	Yan et al. [42]	21	10 (48)	58 (49.5 - 61)	19 (90)	1 (5)
9	Zhao et al. [43]	57	34 (60)	54 (27 - 72)	51 (89)	4 (8)
10	Neelapu et al. [44]	111	68 (67)	58 (23 - 76)	101 (91)	13 (13)
11	Hay et al. [24]	133	93 (70)	54 (20 -73)	93 (70)	16 (17)
12	Turtle et al. [45]	24	ND	61 (40 - 73)	20 (83)	2 (10)
13	Hu et al. [15]	15	9 (60)	32 (7 - 57)	10 (67)	6 (60)
14	Teachey et al. [18]	12	8 (67)	56 (25 - 72)	12 (100)	3 (25)
15	Porter et al. [16]	14	12 (86)	66 (51 - 78)	9 (64)	6 (67)
16	Davila et al. [5]	16	12 (75)	50 (23 - 74)	7 (44)	7 (100)
17	Kalos et al. [46]	3	3 (100)	65 (64 - 77)	3 (100)	3 (100)**

Bogatu et al. (JBI, 2023)


Davila Marcoa L., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in b cell acute lymphoblastic leukemia Sci. Transl. Med., 6 (224) (2014), 10.1126/scitransImed.3008226 (ISSN: 1946-6234, 1946-6242)





Biomark Davila e Hay et a Hong et Hu et al Jacobsc Kalos et Liu et al Neelapu Porter e Sang et Shah et Teachey Topp et Turtle et Yan et a Yan et a Zhao el

IL-2					
IL-4					
IL-6					
IL-8					
IL-10					
IL-15					
IL-2Rα					
TNF-α					
IFN-y					
GM-CS					
CRP					
ferritin					
D-dimer					
VWF					
Ang-2					
MCP-1					
granzyn					
TNFRp!					
MIP1β					
MIP1α					
IL-17					
sIL6R					



Demo Wysocki & Wysocka

LunarFormer pipeline

On Infrastructures

TR

Take-away

Emerging foundations for *industrialised scientific inference* Universal framework for *integrating and organising heterogeneous evidence*

Large Language Models

Are a game-changing foundation.

Transformers are an efficient substrate for modelling language. Alone they are not fit for purpose for scientific reasoning.

Controlling reasoning Scientific reasoning requires complex pipelines. Robust methods already exist to extend LLMs in the direction of rigorous reasoning. (multiple models, trees-of-thought, symbolic augmentation, retrieval augmentation, semantic parsing, differentiable symbolic solvers) Need for a coordination infrastructure.

Very exciting times to do AI for Science!

Thank you for your attention!

Generously supported by:





Engineering and Physical Sciences Research Council







contact: andre.freitas@manchester.ac.uk